⌕
Corcept Therapeutics · CORT · Nasdaq
Tenet 54 · Mixed
Compare
$70.07+1.23%At closeTenet 54 · Mixed
$70.07+0.85 (+1.23%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Corcept Therapeutics (CORT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CORT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 16, 2026 · 08:00 ET
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT +1.2% todayRead at source ↗
● Defense WorldNov 7, 2026 · 05:32 ET
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One equities…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 11:41 ETEARNINGS EXPECTED BY FEB 23
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.…

CORT +1.2% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 19:46 ETEARNINGS EXPECTED BY FEB 23
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript…

CORT +1.2% todayRead at source ↗
● MarketBeatNov 3, 2026 · 19:15 ETEARNINGS EXPECTED BY FEB 23
Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 18:51 ETEARNINGS EXPECTED BY FEB 23
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.…

CORT +1.2% todayRead at source ↗
● Business WireNov 3, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT +1.2% todayRead at source ↗
● Business WireOct 26, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT +1.2% todayRead at source ↗
● Business WireOct 20, 2026 · 16:00 ET
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchOct 19, 2026 · 10:51 ET
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.…

CORT +1.2% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:40 ET
Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price o…

CORT +1.2% todayRead at source ↗
● Defense WorldOct 18, 2026 · 04:50 ETEARNINGS EXPECTED BY FEB 23
Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co.

First Citizens Bank and Trust Co. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 62.0% in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 06:30 ETEARNINGS EXPECTED BY FEB 23
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchOct 15, 2026 · 16:37 ETEARNINGS EXPECTED BY FEB 23
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge

As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.…

CORT +1.2% todayRead at source ↗
● Defense WorldOct 13, 2026 · 05:16 ET
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Has Consensus Target Price of $138.17 According to Analysts

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the company, Marketbeat.com reports. One equi…

CORT +1.2% todayRead at source ↗
● Defense WorldOct 4, 2026 · 14:14 ETEARNINGS EXPECTED BY FEB 23
Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT)

Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on th…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchOct 2, 2026 · 09:01 ET
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.…

CORT +1.2% todayRead at source ↗
● Business WireSep 23, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Corcept Announces Planned Leadership Transition

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchSep 21, 2026 · 12:11 ETEARNINGS EXPECTED BY FEB 23
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.…

CORT +1.2% todayRead at source ↗
● Defense WorldSep 21, 2026 · 04:39 ET
Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $29,842.72 in Stock

Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of …

CORT +1.2% todayRead at source ↗
● Business WireSep 18, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab…

CORT +1.2% todayRead at source ↗
● Zacks Investment ResearchSep 16, 2026 · 11:45 ET
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.…

CORT +1.2% todayRead at source ↗
● FXEmpireSep 16, 2026 · 06:23 ET
Corcept Grows to Mid-Cap on Institutional Support

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.…

CORT +1.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 23. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just CORT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.